Discontinued — last reported Q3 '23
Amphenol Interest Paid decreased by 43.5% to $49.50M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 19.6%, from $41.40M to $49.50M. Over 3 years (FY 2021 to FY 2024), Interest Paid shows an upward trend with a 17.1% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
cf_interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $22.90M | $27.80M | $33.10M | $27.60M | $25.80M | $32.90M | $37.40M | $34.90M | $25.40M | $28.80M | $40.10M | $32.80M | $38.40M | $41.40M | $66.90M | $51.70M | $87.60M | $49.50M |
| QoQ Change | — | +21.4% | +19.1% | -16.6% | -6.5% | +27.5% | +13.7% | -6.7% | -27.2% | +13.4% | +39.2% | -18.2% | +17.1% | +7.8% | +61.6% | -22.7% | +69.4% | -43.5% |
| YoY Change | — | — | — | — | +12.7% | +18.3% | +13.0% | +26.4% | -1.6% | -12.5% | +7.2% | -6.0% | +51.2% | +43.8% | +66.8% | +57.6% | +128.1% | +19.6% |
We use cookies for analytics. See our Privacy and Cookie Policy.